Edition:
United States

Agios Pharmaceuticals Inc (AGIO.O)

AGIO.O on Nasdaq

53.03USD
23 Sep 2016
Change (% chg)

-- (+0.00%)
Prev Close
$53.03
Open
$52.81
Day's High
$54.20
Day's Low
$51.52
Volume
798,960
Avg. Vol
801,070
52-wk High
$89.74
52-wk Low
$33.50

Select another date:

Wed, Sep 7 2016

BRIEF-Agios Pharma says Celgene expects to submit NDA to U.S. FDA for enasidenib

* Celgene corporation expects to submit a new drug application to U.S. FDA for Enasidenib (ag-221)

BRIEF-Agios Pharmaceuticals appoints Andrew Hirsch as chief financial officer

* Glenn Goddard, senior vice president of finance, will be leaving company at end of September to pursue other opportunities

BRIEF-Agios Pharmaceuticals reports qtrly loss per share $1.47

* Collaboration revenue was $7.0 million for quarter ended June 30, 2016, compared to $13.2 million for comparable period in 2015

BRIEF-Agios Pharma reports initial data from phase 1 study of AG-519 in healthy volunteers

* Agios reports initial data from phase 1 study of ag-519 in healthy volunteers Source text for Eikon: Further company coverage: (Bengaluru Newsroom: +1-646-223-8780)

BRIEF-Agios Pharmaceuticals, Celgene establish new collaboration in metabolic immuno-oncology

* Agios and Celgene establish new collaboration in metabolic immuno-oncology and amend certain rights from 2010 agreement

BRIEF-Agios sees 2016 ending cash position of more than $390 mln

* Expects 2016 ending cash position of more than $390 million

BRIEF-Agios, Celgene Corp to defer selection process for allocating rights to certain discovery programs

* Co and Celgene Corp agreed to defer from April 14, 2016 to June 1, 2016 selection process for allocating rights to certain discovery programs

Select another date: